Economic Burden of Genital Herpes Infections
Author Information
Author(s): Chaiyakunapruk Nathorn, Lee Shaun Wen Huey, Kulchaitanaroaj Puttarin, Rayanakorn Ajaree, Lee Haeseon, Looker Katharine Jane, Hutubessy Raymond, Gottlieb Sami L.
Primary Institution: Department of Pharmacotherapy, College of Pharmacy, University of Utah
Hypothesis
This study aims to estimate the global economic impact of genital HSV-2 and HSV-1 infection.
Conclusion
The global costs of genital HSV infection and its consequences are substantial, highlighting the need for HSV prevention interventions.
Supporting Evidence
- The estimated economic burden of genital HSV infection globally was I$35.3 billion in 2016.
- HSV-2 accounted for I$31.2 billion of the total economic burden.
- High- and upper-middle-income countries bore 76.6% of the economic burden.
Takeaway
Genital herpes is very expensive for the world because it causes a lot of health problems and costs money for treatment. Making a vaccine could help save money and lives.
Methodology
The economic burden was calculated using a societal perspective, incorporating healthcare resource utilization and costs from a literature review and expert interviews.
Potential Biases
The estimates relied on expert opinions and assumptions about healthcare resource utilization, which may introduce bias.
Limitations
The study did not include costs associated with non-genital HSV outcomes and was limited by the availability of healthcare resource utilization data in some regions.
Participant Demographics
The study focused on individuals aged 15-49 years globally.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website